Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: The case of MRSA

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Wassenberg, Marjan W M ^a   de Wit, G Ardine ^a,b   van Hout, Ben A ^a   Bonten, Marc J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL TRANSMISSION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFANT; INFECTION CONTROL; INFECTION PREVENTION; MALE; MATHEMATICAL COMPUTING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; DRUG EFFECT; ECONOMICS; MULTIDRUG RESISTANCE; PATHOGENICITY; STAPHYLOCOCCUS INFECTION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANTIINFECTIVE AGENT;

ALGORITHMS; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 77955401775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011562     Document Type: Article

References (37)

1. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, et al. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36: 53-59.
2. Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, et al. (2005) Costs and outcomes among hemodialysis-dependent patients with methicillinresistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26: 175-183.
3. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, et al. (2003) Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36: 592-598.
4. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, et al. (2005) The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26: 166-174.
5. RIVM (2005) European Antimicrobial Resistance Surveillance System. Available: http://www.rivm.nl/earss/database/.
6. NNIS system (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470-485.
7. Styers D, Sheehan DJ, Hogan P, Sahm DF (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5: 2.
8. Wyllie DH, Crook DW, Peto TE (2006) Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 333: 281.
9. Stelfox HT, Bates DW, Redelmeier DA (2003) Safety of patients isolated for infection control. JAMA 290: 1899-1905.
10. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, et al. (2004) Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ 329: 533.
11. Vriens M, Blok H, Fluit A, Troelstra A, van der Werken C, et al. (2002) Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 21: 782-786.
12. Melzer M, Eykyn SJ, Gransden WR, Chinn S (2003) Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 37: 1453-1460.
13. Tacconelli E, Pop-Vicas AE, D'Agata EM (2006) Increased mortality among elderly patients with meticillin-resistant Staphylococcus aureus bacteraemia. J Hosp Infect 64: 251-256.
14. Shurland S, Zhan M, Bradham DD, Roghmann MC (2007) Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28: 273-279.
15. Barnett AG, Batra R, Graves N, Edgeworth J, Robotham J, et al. (2009) Using a longitudinal model to estimate the effect of methicillin-resistant Staphylococcus aureus infection on length of stay in an intensive care unit. Am J Epidemiol 170: 1186-1194.
16. Linnemann CC, Jr., Mason M, Moore P, Korfhagen TR, Staneck JL (1982) Methicillin-resistant Staphylococcus aureus: experience in a general hospital over four years. Am J Epidemiol 115: 941-950.
17. Thompson RL, Cabezudo I, Wenzel RP (1982) Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 97: 309-317.
18. Jernigan JA, Clemence MA, Stott GA, Titus MG, Alexander CH, et al. (1995) Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 16: 686-696.
19. Robicsek A, Beaumont JL, Paule SM, Hacek DM, Thomson RB, Jr., et al. (2008) Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 148: 409-418.
20. van Rijen M, Bonten M, Wenzel R, Kluytmans J (2008) Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev Oct 8: CD006216.
21. Werkgroep Infectiepreventie (2008) MRSA, Ziekenhuis. Available: http://www.wip.nl/free_content/richtlijnen/mrsa%20ziekenhuis080310.pdf.
22. Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, et al. (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145: 646-653.
23. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156: 127-132.
24. Oostenbrink JB (2004) Standaard kostprijzen en rekenwaarden, bijlage bij "Handleiding voor Kostenonderzoek; methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg". Amstelveen: College voor Zorgverzekeringen.
25. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, et al. (2009) Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 49: 997-1005.
26. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 282: 1745-1751.
27. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK (2005) Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 11: 466-471.
28. West TE, Guerry C, Hiott M, Morrow N, Ward K, et al. (2006) Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect Control Hosp Epidemiol 27: 233-238.
29. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, et al. (2006) Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 27: 1009-1017.
30. Papia G, Louie M, Tralla A, Johnson C, Collins V, et al. (1999) Screening highrisk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 20: 473-477.
31. Lee BY, Bailey RR, Smith KJ, Muder RR, Strotmeyer ES, et al. (2010) Universal Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance for Adults at Hospital Admission: An Economic Model and Analysis. Infect Control Hosp Epidemiol 31: 598-606.
32. Karchmer TB, Durbin LJ, Simonton BM, Farr BM (2002) Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 51: 126-132.
33. Bjorholt I, Haglind E (2004) Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis 23: 688-695.
34. Casparie AF, van Hout BA, Simoons ML (1998) Guidelines and costs. Ned Tijdschr Geneeskd 142: 2075-2077.
35. Raad voor de Volksgezondheid en Zorg (2006) Zinnige en duurzame zorg. Zoetermeer.
36. van Rijen MM, Kluytmans JA (2009) Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital. Eur J Clin Microbiol Infect Dis 28: 1245-1252.
37. Graves N, Weinhold D, Tong E, Birrell F, Doidge S, et al. (2007) Effect of healthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 28: 280-292.